BG106480A - 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents - Google Patents
3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agentsInfo
- Publication number
- BG106480A BG106480A BG06480A BG10648002A BG106480A BG 106480 A BG106480 A BG 106480A BG 06480 A BG06480 A BG 06480A BG 10648002 A BG10648002 A BG 10648002A BG 106480 A BG106480 A BG 106480A
- Authority
- BG
- Bulgaria
- Prior art keywords
- amino
- pyrazole derivatives
- preparation
- antitumor agents
- branched
- Prior art date
Links
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37283199A | 1999-08-12 | 1999-08-12 | |
| PCT/US2000/006699 WO2001012189A1 (fr) | 1999-08-12 | 2000-05-05 | Derives de 3(5)-amino-pyrazole, leur procede de fabrication et leur emploi comme agents anti-tumoraux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG106480A true BG106480A (en) | 2002-09-30 |
Family
ID=23469802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG06480A BG106480A (en) | 1999-08-12 | 2002-03-05 | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US7034049B1 (fr) |
| EP (1) | EP1202733B1 (fr) |
| JP (1) | JP2003507329A (fr) |
| KR (1) | KR20020060160A (fr) |
| CN (1) | CN1373662A (fr) |
| AP (1) | AP2002002442A0 (fr) |
| AR (1) | AR026122A1 (fr) |
| AT (1) | ATE305782T1 (fr) |
| AU (1) | AU4971400A (fr) |
| BG (1) | BG106480A (fr) |
| BR (1) | BR0013143A (fr) |
| CA (1) | CA2383555C (fr) |
| CZ (1) | CZ2002422A3 (fr) |
| DE (1) | DE60023012T2 (fr) |
| DK (1) | DK1202733T3 (fr) |
| EA (1) | EA005373B1 (fr) |
| EE (1) | EE200200065A (fr) |
| ES (1) | ES2249270T3 (fr) |
| GE (1) | GEP20053476B (fr) |
| HK (1) | HK1046866A1 (fr) |
| HR (1) | HRP20020128A2 (fr) |
| HU (1) | HUP0203542A3 (fr) |
| IL (1) | IL147923A0 (fr) |
| IS (1) | IS6265A (fr) |
| MA (1) | MA25493A1 (fr) |
| MX (1) | MXPA02001498A (fr) |
| NO (1) | NO20020684L (fr) |
| NZ (1) | NZ517237A (fr) |
| OA (1) | OA12046A (fr) |
| PE (1) | PE20010130A1 (fr) |
| PL (1) | PL353455A1 (fr) |
| SK (1) | SK1812002A3 (fr) |
| WO (1) | WO2001012189A1 (fr) |
| YU (1) | YU9602A (fr) |
| ZA (1) | ZA200201511B (fr) |
Families Citing this family (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9901691D0 (en) | 1999-01-26 | 1999-03-17 | Cerebrus Ltd | Chemical compounds |
| JP2003507329A (ja) * | 1999-08-12 | 2003-02-25 | フアルマシア・イタリア・エツセ・ピー・アー | ３（５）−アミノ−ピラゾール誘導体、それらの製造方法および抗腫瘍薬としてのそれらの使用 |
| AU2972701A (en) | 2000-02-07 | 2001-08-14 | Bristol Myers Squibb Co | 3-aminopyrazole inhibitors of cyclin dependent kinases |
| JP2004507455A (ja) | 2000-04-25 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途 |
| DE10037310A1 (de) | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
| AU2001280009A1 (en) * | 2000-08-31 | 2002-03-13 | Pfizer Products Inc. | Pyrazole derivatives and their use as protein kinase inhibitors |
| US20020103185A1 (en) * | 2000-08-31 | 2002-08-01 | Sanner Mark A. | Pyrazole derivatives |
| AU2002215053A1 (en) * | 2000-11-27 | 2002-06-24 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| US6455559B1 (en) * | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| EP1379524A2 (fr) * | 2001-01-26 | 2004-01-14 | Pharmacia Italia S.p.A. | Derives de chromane, procede de preparation et d'utilisation de ces derives en tant qu'agents antitumoraux |
| DE60210058T2 (de) * | 2001-03-02 | 2006-11-09 | F. Hoffmann-La Roche Ag | Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten |
| SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| US6727364B2 (en) | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| JP2004535411A (ja) | 2001-05-25 | 2004-11-25 | ブリストルーマイヤーズ スクイブ カンパニー | マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物 |
| DE10148617A1 (de) * | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| DE10148618B4 (de) * | 2001-09-25 | 2007-05-03 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| DE60233420D1 (de) * | 2001-09-27 | 2009-10-01 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
| SE0103710D0 (sv) | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
| AU2002362030A1 (en) * | 2001-11-27 | 2003-06-10 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| US6593477B1 (en) | 2002-10-29 | 2003-07-15 | Eastman Kodak Company | Synthesis of 3-acylaminopyrazoles |
| CA2508990C (fr) * | 2002-12-10 | 2013-05-28 | Virochem Pharma Inc. | Composes et procedes de traitement ou de prevention d'infections a flavivirus |
| UA81790C2 (uk) | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| AU2003294376A1 (en) * | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heteroaryl compounds |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| CA2519899A1 (fr) * | 2003-03-27 | 2004-10-14 | Merck & Co., Inc. | Compositions ophtalmiques pour traiter une hypertension oculaire |
| SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| GEP20094664B (en) | 2003-05-22 | 2009-04-10 | Nerviano Medical Sciences Srl | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| WO2005009344A2 (fr) | 2003-06-05 | 2005-02-03 | Elan Pharmaceuticals, Inc. | Amino acide amidyle pyrazoles acyles et composes relatifs |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| CA2552558A1 (fr) * | 2004-01-16 | 2005-08-11 | Wyeth | Inhibiteurs a base de sulfonamides heterocycliques de la production des beta-amyloides contenant un azole |
| WO2005072731A1 (fr) * | 2004-01-29 | 2005-08-11 | X-Ceptor Therapeutics, Inc. | Derives de 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide et composes apparentes utiles comme modulateurs des recepteurs lies a l'oestrogene dans le traitement du cancer, de l'arthrite rhumatoide ou de troubles neurologiques |
| WO2005075435A1 (fr) | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulateurs de transporteurs de type cassette de liaison a l'atp |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| TW200526204A (en) | 2004-02-03 | 2005-08-16 | Pharmacia Italia Spa | 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
| WO2005118543A1 (fr) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | Inhibiteur des kinases et utilisation de cet inhibiteur |
| US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
| SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| BRPI0518798A2 (pt) * | 2004-12-03 | 2008-12-09 | Transtech Pharma Inc | composto, composiÇço farmacÊutica, e, mÉtodos para tratar diabete tipo ii e para tratar uma condiÇço ou distérbio |
| SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| US7361672B2 (en) | 2004-12-23 | 2008-04-22 | Hoffmann-La Roche Inc. | Heteroarylacetamide inhibitors of factor Xa |
| FR2880540B1 (fr) * | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
| WO2008007113A2 (fr) * | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
| RU2420525C2 (ru) | 2005-07-11 | 2011-06-10 | Мицубиси Танабе Фарма Корпорейшн | Производные оксимов и их получение |
| WO2007009898A1 (fr) | 2005-07-19 | 2007-01-25 | Nerviano Medical Sciences S.R.L. | Composes 1h-thieno[2,3-c]pyrazole servant d'inhibiteurs de kinase |
| KR20080090381A (ko) * | 2005-08-29 | 2008-10-08 | 제라드 엠. 하우지 | 테라뮤틴 조절물질 |
| AR058705A1 (es) | 2005-12-23 | 2008-02-20 | Astrazeneca Ab | Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1) |
| US20070203224A1 (en) * | 2006-01-09 | 2007-08-30 | University Of Southern California | Small-molecules for treating cancer and abnormal cell proliferation disorders |
| WO2007095383A2 (fr) * | 2006-02-15 | 2007-08-23 | Myriad Genetics, Inc. | Promédicaments |
| UY30183A1 (es) * | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| US8211925B2 (en) * | 2006-04-28 | 2012-07-03 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
| WO2007129052A1 (fr) * | 2006-05-03 | 2007-11-15 | Astrazeneca Ab | Dérivés de pyrazole et leur emploi en tant qu'inhibiteurs de pi3k |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| WO2008084873A1 (fr) * | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | Dérivé oxime |
| WO2008084872A1 (fr) | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | Dérivé d'hydrazone |
| JP5491871B2 (ja) * | 2007-02-28 | 2014-05-14 | アドビナス セラピュティックス プライベート リミテッド | グルコキナーゼ活性化因子としての２，２，２−三置換アセトアミド誘導体、その方法及び薬学的応用 |
| KR100923540B1 (ko) * | 2007-11-23 | 2009-10-27 | 한국과학기술연구원 | 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법 |
| AU2009261683A1 (en) * | 2008-06-19 | 2009-12-23 | Astrazeneca Ab | Pyrazole compounds 436 |
| NZ590355A (en) | 2008-07-10 | 2013-01-25 | Yakult Honsha Kk | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
| JP5683462B2 (ja) | 2008-07-24 | 2015-03-11 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| ME02642B (me) * | 2008-12-05 | 2017-06-20 | Abbvie Inc | Sulfonamid derivati i kao BCL- 2 selektivni agensi za induciranje apoptoze namijenjeni liječenju raka i imunih bolesti |
| EP4242206A1 (fr) * | 2009-01-30 | 2023-09-13 | Novartis AG | Forme crystalline du chlorhydrate de n-{(1-5)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophene carboxamide |
| US20120045459A1 (en) * | 2009-05-05 | 2012-02-23 | Van Andel Research Institute | Methods for Treating Autophagy-Related Disorders |
| WO2011022473A1 (fr) * | 2009-08-19 | 2011-02-24 | Ambit Biosciences Corporation | Composés biaryles et procédés dutilisation de ceux-ci |
| CN102574843B (zh) | 2009-10-22 | 2015-06-17 | 法博太科制药有限公司 | 抗纤维化剂的稠环类似物 |
| US20120316171A1 (en) * | 2009-11-05 | 2012-12-13 | Tamas Oravecz | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer |
| KR101955691B1 (ko) * | 2010-03-30 | 2019-03-07 | 베르선 코포레이션 | 트롬빈 억제제로서의 다중치환된 방향족 화합물 |
| JP5855095B2 (ja) | 2010-06-07 | 2016-02-09 | ノボメディックス, エルエルシーNovomedix, Llc | フラニル化合物およびその使用 |
| EP2582666B1 (fr) | 2010-06-16 | 2014-08-13 | Purdue Pharma L.P. | Indoles à substitution aryle et leur utilisation en tant que bloqueur des canaux sodium |
| AU2011323617B2 (en) | 2010-11-03 | 2015-02-05 | Corteva Agriscience Llc | Pesticidal compositions and processes related thereto |
| US9073895B2 (en) * | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| EP2614065B1 (fr) | 2010-12-17 | 2017-04-19 | Nerviano Medical Sciences S.r.l. | Dérivés de pyrazolo-quinazoline substitués à titre d'inhibiteurs de kinases |
| US20140249105A1 (en) * | 2011-07-25 | 2014-09-04 | Diverchim | Novel ceramide analogues, processes for preparing same and uses thereof |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| EP2755652B1 (fr) * | 2011-09-16 | 2021-06-02 | Novartis AG | Hétérocyclyle carboxamides n-substitués |
| US8937083B2 (en) | 2011-10-26 | 2015-01-20 | DowAgroSciences, LLC | Pesticidal compositions and processes related thereto |
| US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| US20130291227A1 (en) | 2012-04-27 | 2013-10-31 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
| CN103936637B (zh) * | 2013-01-18 | 2016-04-06 | 北京大学 | E-3,4-二羟苯乙烯基亚砜类化合物的制备方法及其作为神经保护药物的应用 |
| MA38394B1 (fr) | 2013-03-15 | 2018-04-30 | Glaxosmithkline Ip Dev Ltd | Dérivés pyridine utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret) |
| JP6479749B2 (ja) | 2013-03-15 | 2019-03-06 | ヴァーセオン コーポレイション | トロンビン阻害剤としてのハロゲノピラゾール |
| RU2019101889A (ru) | 2013-03-15 | 2019-03-28 | Версеон Корпорейшн | Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз |
| UA115264C2 (uk) | 2013-03-15 | 2017-10-10 | Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед | Піридинові похідні як інгібітори реаранжованої у процесі трансфекції (ret) кінази |
| WO2014170350A1 (fr) * | 2013-04-17 | 2014-10-23 | Albert Ludwigs Universität Freiburg | Composés destinés à être utilisés comme inhibiteurs de bromodomaine |
| CN103265535B (zh) * | 2013-05-14 | 2015-06-17 | 浙江医药高等专科学校 | 抗肿瘤化合物、其制备方法和用途 |
| EP3039021A1 (fr) * | 2013-08-30 | 2016-07-06 | Ambit Biosciences Corporation | Composés de biaryle acétamide et procédés d'utilisation de ceux-ci |
| MX2016004940A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Proceso para la preparacion de compuestos plaguicidas. |
| MX2016004945A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Procesos para la preparacion de compuestos plaguicidas. |
| JP2016535010A (ja) | 2013-10-17 | 2016-11-10 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除性化合物の製造方法 |
| KR20160072155A (ko) | 2013-10-17 | 2016-06-22 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
| CN105636446B (zh) | 2013-10-17 | 2018-07-13 | 美国陶氏益农公司 | 制备杀虫化合物的方法 |
| EP3057430A4 (fr) | 2013-10-17 | 2017-09-13 | Dow AgroSciences LLC | Procédés de préparation de composés pesticides |
| KR20160074540A (ko) | 2013-10-17 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
| US9491944B2 (en) | 2013-10-22 | 2016-11-15 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| RU2016119553A (ru) | 2013-10-22 | 2017-12-04 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Синергетические пестицидные композиции и связанные с ними способы |
| KR20160074634A (ko) | 2013-10-22 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 상승작용적 살충 조성물 및 관련 방법 |
| JP2016535026A (ja) | 2013-10-22 | 2016-11-10 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
| WO2015061142A1 (fr) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Compositions pesticides synergiques et procédés associés |
| US9788545B2 (en) | 2013-10-22 | 2017-10-17 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| NZ719754A (en) | 2013-10-22 | 2017-06-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| WO2015061161A1 (fr) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Compositions pesticides et procédés associés |
| MX2016005306A (es) | 2013-10-22 | 2016-08-12 | Dow Agrosciences Llc | Composiciones pesticidas sinergicas y metodos relacionados. |
| ES2745988T3 (es) | 2013-10-22 | 2020-03-04 | Dow Agrosciences Llc | Composiciones plaguicidas y métodos relacionados |
| EP3060045A4 (fr) | 2013-10-22 | 2017-04-05 | Dow AgroSciences LLC | Compositions pesticides synergiques et procédés associés |
| JP2016536304A (ja) | 2013-10-22 | 2016-11-24 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
| WO2015061145A1 (fr) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Compositions pesticides synergiques et procédés associés |
| MX2016005317A (es) | 2013-10-22 | 2016-08-12 | Dow Agrosciences Llc | Composiciones pesticidas y metodos relacionados. |
| AR098105A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones plaguicidas y métodos relacionados |
| RU2016119576A (ru) | 2013-10-22 | 2017-11-28 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Синергетические пестицидные композиции и связанные с ними способы |
| WO2015061155A1 (fr) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Compositions pesticides et procédés associés |
| WO2015143653A1 (fr) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | Inhibiteurs de la kinase trka, compositions et méthodes associées |
| CN106488909A (zh) | 2014-07-31 | 2017-03-08 | 美国陶氏益农公司 | 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法 |
| CA2954747A1 (fr) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Lcc | Procede pour la preparation de 3-(3-methyl-phenyl-1h-pyrazol-1-yl)pyridine |
| CA2954631A1 (fr) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Procede pour la preparation de 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| CA2958058A1 (fr) | 2014-08-19 | 2016-02-25 | Dow Agrosciences Llc | Procede de preparation de 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| JP6538153B2 (ja) | 2014-09-10 | 2019-07-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）阻害剤としての新規な化合物 |
| EP3517526B1 (fr) | 2014-09-10 | 2020-08-19 | GlaxoSmithKline Intellectual Property Development Limited | Pyridinones en tant qu'inhibiteurs redisposés pendant la transfection (ret) |
| CA2960985A1 (fr) | 2014-09-12 | 2016-03-17 | Dow Agrosciences Llc | Procede de preparation de 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| WO2016044662A1 (fr) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Composés de pyridone substituée par pyrazolyl en tant qu'inhibiteurs de sérine protéase |
| GB201416513D0 (en) * | 2014-09-18 | 2014-11-05 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| EP3261639B1 (fr) | 2015-02-27 | 2022-08-24 | Verseon International Corporation | Composés pyrazole substitués à utiliser en tant qu'inhibiteurs de sérine protéase |
| CA2978170C (fr) | 2015-03-09 | 2024-02-27 | Aurigene Discovery Technologies Limited | Derives de pyrazolo[1,5-a][1,3,5]triazine et de pyrazolo[1,5-a]pyrimidine utilises en tant qu'inhibiteurs de cdk |
| EP3291813A4 (fr) | 2015-05-06 | 2019-01-02 | The Regents of The University of California | Modulateurs de k-ras |
| CA2987552A1 (fr) | 2015-06-04 | 2016-12-08 | Aurigene Discovery Technologies Limited | Derives heterocyclyle substitues en tant qu'inhibiteurs de cdk |
| DK3497099T3 (da) | 2016-08-12 | 2022-05-23 | Athenex Inc | Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade |
| ES2922932T3 (es) * | 2016-12-29 | 2022-09-21 | Enyo Pharma | Derivados de tiofeno como agentes antivirales |
| US10233155B2 (en) | 2016-12-29 | 2019-03-19 | Dow Agrosciences Llc | Processes for the preparation of pesticide compounds |
| US10100033B2 (en) | 2016-12-29 | 2018-10-16 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| EP3577103A1 (fr) | 2017-02-03 | 2019-12-11 | Certa Therapeutics Pty Ltd. | Composés anti-fibrotiques |
| CA3056886A1 (fr) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Dihydroindene-4-carboxamides substitues, leurs analogues et procedes d'utilisation correspondant |
| TW201900638A (zh) | 2017-04-20 | 2019-01-01 | 加州大學董事會 | Ｋ－ｒａｓ調節劑 |
| EP3720436A4 (fr) | 2017-12-06 | 2021-06-02 | Lin Bioscience, Pty Ltd. | Inhibiteurs de tubuline |
| JP7184383B2 (ja) * | 2018-02-01 | 2022-12-06 | ザ・ユニバーシティ・オブ・シドニー | 抗癌性化合物 |
| EP3774768A4 (fr) * | 2018-04-04 | 2022-01-05 | Aurigene Discovery Technologies Limited | Dérivés de pyrazole substitués utilisés en tant qu'inhibiteurs sélectifs de cdk12/13 |
| US11174263B2 (en) * | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
| KR20210117261A (ko) | 2018-12-31 | 2021-09-28 | 바이오메아 퓨전, 인크. | 메닌-mll 상호작용의 비가역적 억제제 |
| AU2021213257A1 (en) * | 2020-01-29 | 2022-08-25 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN111793034B (zh) * | 2020-07-24 | 2021-11-19 | 华中科技大学 | 苯并咪唑盐衍生物与制备抗肿瘤药物的应用 |
| AU2021359129A1 (en) * | 2020-10-16 | 2023-06-01 | Proxygen Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
| TW202229268A (zh) * | 2020-12-22 | 2022-08-01 | 大陸商上海拓界生物醫藥科技有限公司 | Ｃｄｋ２抑制劑及其製備方法 |
| AU2022331496A1 (en) | 2021-08-20 | 2024-02-29 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer |
| KR20240133695A (ko) * | 2021-12-10 | 2024-09-04 | 프로테나 바이오사이언시즈 리미티드 | Dyrk1a 억제제로서의 헤테로시클릭 화합물 |
| WO2023203172A1 (fr) * | 2022-04-20 | 2023-10-26 | Proxygen Gmbh | Composés d'ubiquitine ligase cullin ring hétérocycliques et leurs utilisations |
| CN116496151B (zh) * | 2023-04-26 | 2024-08-23 | 长沙医学院 | 一种利用Catellani策略制备芴酮衍生物的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162360A (en) | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
| DE69532817T2 (de) | 1994-11-10 | 2005-01-13 | Millenium Pharmaceuticals, Inc., Cambridge | Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose |
| DE69720051T2 (de) | 1996-12-03 | 2003-09-04 | Banyu Pharmaceutical Co., Ltd. | Harnstoffderivate |
| AU7726898A (en) | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
| ES2155045T3 (es) | 1997-12-22 | 2007-02-01 | Bayer Pharmaceuticals Corp. | Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo. |
| JP4403482B2 (ja) | 1997-12-22 | 2010-01-27 | バイエル コーポレイション | 置換複素環尿素合成のための中間体およびその製造方法 |
| JP2003507329A (ja) * | 1999-08-12 | 2003-02-25 | フアルマシア・イタリア・エツセ・ピー・アー | ３（５）−アミノ−ピラゾール誘導体、それらの製造方法および抗腫瘍薬としてのそれらの使用 |
| US6455559B1 (en) * | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
-
2000
- 2000-05-05 JP JP2001516535A patent/JP2003507329A/ja not_active Withdrawn
- 2000-05-05 IL IL14792300A patent/IL147923A0/xx unknown
- 2000-05-05 CN CN00812732A patent/CN1373662A/zh active Pending
- 2000-05-05 KR KR1020027001857A patent/KR20020060160A/ko not_active Application Discontinuation
- 2000-05-05 EP EP00931906A patent/EP1202733B1/fr not_active Expired - Lifetime
- 2000-05-05 AP APAP/P/2002/002442A patent/AP2002002442A0/en unknown
- 2000-05-05 CA CA002383555A patent/CA2383555C/fr not_active Expired - Fee Related
- 2000-05-05 DE DE60023012T patent/DE60023012T2/de not_active Expired - Fee Related
- 2000-05-05 MX MXPA02001498A patent/MXPA02001498A/es active IP Right Grant
- 2000-05-05 ES ES00931906T patent/ES2249270T3/es not_active Expired - Lifetime
- 2000-05-05 EA EA200200248A patent/EA005373B1/ru not_active IP Right Cessation
- 2000-05-05 AU AU49714/00A patent/AU4971400A/en not_active Abandoned
- 2000-05-05 HU HU0203542A patent/HUP0203542A3/hu unknown
- 2000-05-05 NZ NZ517237A patent/NZ517237A/xx unknown
- 2000-05-05 SK SK181-2002A patent/SK1812002A3/sk unknown
- 2000-05-05 DK DK00931906T patent/DK1202733T3/da active
- 2000-05-05 PL PL00353455A patent/PL353455A1/xx not_active Application Discontinuation
- 2000-05-05 YU YU9602A patent/YU9602A/sh unknown
- 2000-05-05 BR BR0013143-1A patent/BR0013143A/pt not_active Application Discontinuation
- 2000-05-05 GE GE4758A patent/GEP20053476B/en unknown
- 2000-05-05 CZ CZ2002422A patent/CZ2002422A3/cs unknown
- 2000-05-05 AT AT00931906T patent/ATE305782T1/de not_active IP Right Cessation
- 2000-05-05 EE EEP200200065A patent/EE200200065A/xx unknown
- 2000-05-05 US US10/048,486 patent/US7034049B1/en not_active Expired - Fee Related
- 2000-05-05 WO PCT/US2000/006699 patent/WO2001012189A1/fr active IP Right Grant
- 2000-05-05 OA OA1200200051A patent/OA12046A/en unknown
- 2000-05-15 PE PE2000000453A patent/PE20010130A1/es not_active Application Discontinuation
- 2000-05-16 AR ARP000102347A patent/AR026122A1/es unknown
- 2000-09-22 US US09/667,603 patent/US6218418B1/en not_active Expired - Fee Related
-
2002
- 2002-02-11 IS IS6265A patent/IS6265A/is unknown
- 2002-02-11 NO NO20020684A patent/NO20020684L/no not_active Application Discontinuation
- 2002-02-12 HR HR20020128A patent/HRP20020128A2/hr not_active Application Discontinuation
- 2002-02-22 ZA ZA200201511A patent/ZA200201511B/xx unknown
- 2002-03-05 BG BG06480A patent/BG106480A/xx unknown
- 2002-03-11 MA MA26549A patent/MA25493A1/fr unknown
- 2002-11-26 HK HK02108532.6A patent/HK1046866A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG106480A (en) | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents | |
| AP1853A (en) | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents. | |
| NZ527123A (en) | Oxazolyl-pyrazole derivatives as kinase inhibitors | |
| EA200200249A1 (ru) | Производные 3(5)-уреидопиразола, способ их получения и их применение в качестве противоопухолевых агентов | |
| AP1895A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents. | |
| CA2290918A1 (fr) | Derives bicycliques heteroaromatiques utiles comme agents anticancereux | |
| CA2413424A1 (fr) | Derives bicycliques substitues destines au traitement de la croissance cellulaire anormale | |
| CA2401229A1 (fr) | Composes azapolycycliques a fusion aryle | |
| WO2004020431A3 (fr) | Nouveaux dérivées de benzoimidazole utilisés en tant qu'agents antiprolifératifs | |
| MA26679A1 (fr) | Derives de quinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| AU2002359164A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| DK0647219T3 (da) | Derivater i vitamin D-serien modificeret i 20-positionen, fremgangsmåde til fremstilling af sådanne derivater, mellemprodukter itl brug ved fremgangsmåde, farmaceutiske præparater indeholdende derivaterne samt deres anvendelse ved fremstilling af lægemidler | |
| NO20004162D0 (no) | Antitumor agens | |
| RU94046141A (ru) | Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция | |
| MXPA04000407A (es) | Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales. | |
| MXPA04005157A (es) | Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. | |
| MY128818A (en) | Ethanesulfonyl-piperidine derivatives | |
| HUP0302255A2 (hu) | Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AU2002362008A1 (en) | Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease | |
| ECSP003473A (es) | Derivados del 3(5)- amino - pirazol, proceso para su preparacion y su uso como agentes antitumores | |
| ECSP003611A (es) | Derivados de 3(5)-ureido- pirazol, procedimiento para su preparacion y su utilizacion como agentes antitumorales |